LMOD1

Across TCGA pan-cancer cohorts, LMOD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LMOD1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LMOD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LMOD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where LMOD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	IV	0.198	0.830	.024	15	view →
GBM	OS	Quartile	All	0.405	0.734	.008	13	view →
PDAC	OS	Median	III,IV	0.543	0.322	.014	10	view →
LUAD	DFS	Median	II,III,IV	0.740	0.966	.002	9	view →
LSCC	DFS	Median	All	0.865	0.711	.021	4	view →
HNSC	DFS	Tertile	III,IV	0.888	0.741	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LMOD1–CCRCC (OS)

Open the CCRCC breakdown →